LON:CLIN Clinigen Group (CLIN) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Clinigen Group Stock (LON:CLIN) Get Clinigen Group alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume539,375 shsAverage Volume1.83 million shsMarket Capitalization£1.23 billionP/E Ratio64.69Dividend Yield0.82%Price TargetN/AConsensus RatingN/A Company Overview Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom. Read More Receive CLIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinigen Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLIN Stock News HeadlinesClinigen Appoints Greg Skalicky as Chief Executive OfficerJuly 20, 2026 | finance.yahoo.comClinigen boost unlicensed drugs business with Quantum takeoverJune 25, 2026 | uk.finance.yahoo.comElon says "don't save money." Is he right?Elon Musk says there will be no poverty in the future and that money won't matter in ten years. Until that day arrives, one existing program already pays out on a similar promise. The Patriot Income Plan issues 42 payouts a year - roughly once a week - funded by partnerships that control America's critical infrastructure, not tax dollars. Enrollees have historically received a 10 percent annual yield, and since 2020 the average partnership has produced 20 percent average annual gains.July 30 at 1:00 AM | Freedom Financial (Ad)Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort Enteral Solution, Human Milk-Based Product in JapanFebruary 12, 2026 | finanznachrichten.deComparator Drug Sourcing Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Clinigen, BAP Pharma Group, Thermo Fisher Scientific, Laboratory Corporation of America ...January 26, 2026 | finance.yahoo.comClinigence Holdings (NUTX) Receives a Buy from Maxim GroupApril 9, 2025 | markets.businessinsider.comEvotec Shares Jump After Triton Acquires StakeNovember 11, 2024 | marketwatch.comTriton Weighs Takeover Deal for Drug Developer EvotecNovember 11, 2024 | finance.yahoo.comSee More Headlines CLIN Stock Analysis - Frequently Asked Questions How were Clinigen Group's earnings last quarter? Clinigen Group plc (LON:CLIN) released its earnings results on Thursday, September, 17th. The company reported $65.60 EPS for the quarter, beating analysts' consensus estimates of $63.50 by $2.10. How do I buy shares of Clinigen Group? Shares of CLIN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Clinigen Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Albemarle (ALB), First Hawaiian (FHB), GE Aerospace (GE) and Company Calendar Last Earnings9/17/2020Today7/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Delivery Sub-IndustryTrading Current SymbolLON:CLIN CIKN/A Webwww.clinigengroup.com Phone+44-1283-495010FaxN/AEmployees1,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio64.69 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio90.77 Current Ratio1.89 Quick Ratio1.48 Sales & Book Value Annual Sales£565.60 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.48 Book ValueGBX 341.90 per share Price / BookN/AMiscellaneous Outstanding Shares133,367,000Free FloatN/AMarket Cap£1.23 billion OptionableNot Optionable BetaN/A The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (LON:CLIN) was last updated on 7/30/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBREAKING: Bill Gates Says It’s “Worth 10 Microsofts”Nvidia is up 203% this year. Microsoft, Amazon, Apple, and Alphabet have each surged between 36% and 62%. But ...Traders Agency | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe oil crisis is spreading faster than you thinkTanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG c...Golden Portfolio | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinigen Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Clinigen Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.